ASC Ownership: The Orthopedic Wealth Lever

No single financial decision in an orthopedic surgeon's career creates more wealth than buying into a surgeon-owned ambulatory surgery center. ASC distributions — separate from your clinical income — routinely add $300K–$1M+ per year to an established partner's take-home. Over a 20-year career, the gap between an ortho surgeon who owns ASC equity and one who doesn't can exceed $5M in after-tax wealth.

This guide covers how ASC ownership actually works financially: the economics, the buy-in mechanics, how distributions are structured and taxed, what Anti-Kickback safe harbors require, what to review before committing, and what exit looks like when the time comes.

Why ASC economics favor orthopedic surgeons

Ambulatory surgery centers operate with structural advantages over hospital outpatient departments: lower overhead, no trauma call burden, no ER cross-subsidy, and procedure mix that skews toward elective, high-margin work. For orthopedics specifically, the economics are especially favorable:

• High procedure volume. Arthroscopy, carpal tunnel, hand surgery, foot/ankle procedures, and same-day joint replacement all generate multiple cases per day per surgeon. An active ortho ASC runs 20–40 cases per OR day.
• Strong reimbursement trends. Medicare's 2026 final rule (CMS-1834-FC) removed 285 procedures from the Inpatient Procedure Only (IPO) list — the majority musculoskeletal — allowing more ortho cases to shift from hospital to ASC settings. Total hip (CPT 27130), total knee (CPT 27447), and selected spinal procedures that previously required inpatient stays can now be performed at certified ASCs for qualifying patients.¹
• Predictable payer mix. Elective ortho volume skews toward commercial patients with good insurance, particularly in private-practice settings. Commercial rates at ASCs run 2–4× Medicare, which drives margins.
• Capital efficiency. A well-run orthopedic ASC typically achieves 25–40% EBITDA margins on facility revenue — materially higher than most physician practices.

The numbers: what ASC ownership actually produces

A well-run orthopedic ASC with 8–12 surgeon-owners might look like this:

These distributions are on top of your clinical professional fees. You perform the case, bill your professional fee through your practice (physician income), and also receive facility distributions as an ASC owner (investment income). Both streams flow from the same case.

How the buy-in works

When a group invites a new surgeon to buy into the ASC, the offer has several components worth understanding before you sign anything:

How buy-in price is calculated

Buy-in price typically reflects a discount to enterprise value for new surgeon slots. Enterprise value is usually based on an EBITDA multiple (4–7× for surgeon-to-surgeon transactions, higher when corporate buyers are involved). A 10% stake in an ASC with $500K EBITDA might be priced at:

• Enterprise value = $500K × 5.5 = $2.75M
• Your 10% stake = $275K

Established high-volume ASCs command higher multiples; newer or struggling facilities offer lower entry prices but more risk. The buy-in price is not always negotiable, but the terms (payment schedule, financing structure, distribution priority) often are.

New money vs. existing interest purchase

Two structures exist: buying a new slot (the ASC issues new ownership units, using capital to fund growth or equipment) or buying an existing partner's interest (a departing surgeon sells their stake to you). New money buy-ins dilute existing partners; the group must vote to approve. Secondhand purchases are bilateral transactions between you and the selling surgeon.

Financing the buy-in

Most orthopedic ASCs offer financed buy-ins via promissory notes, typically:

• 5–7 year term
• 6–8% interest rate
• Offset by quarterly distributions (i.e., distributions fund the note payments)

At a healthy ASC, distributions often exceed annual note payments in Year 1 — meaning you receive net cash even while paying off the buy-in. The interest on the note is typically deductible against your ASC K-1 income as investment interest expense (consult a CPA on proper structuring).

Break-even timeline

At most established orthopedic ASCs, surgeon-owners recoup their buy-in investment in 2–4 years through distributions, with purely positive cash flow thereafter. Use the ASC Investment ROI Calculator to model your specific offer.

How distributions are calculated and paid

Two distribution models are used in orthopedic ASCs, each with Anti-Kickback implications:

Pro-rata by ownership percentage

If you own 10% of the ASC, you receive 10% of all distributions regardless of your individual case contribution. Simple and AKS-clean, but it rewards passive partners and can create free-rider dynamics in groups where procedural volume is unequal.

Production-weighted distributions

Distributions tied to each surgeon's individual case volume at the facility. Intuitively fair — you get paid for what you bring — but legally complex. A pure pay-per-case structure can look like a kickback, since you're being compensated based on referrals to a facility you own. These arrangements require careful structuring within the AKS safe harbor framework by a healthcare attorney.

Hybrid models

Most modern orthopedic ASCs use hybrid approaches: a base pro-rata distribution (compliant) with a volume-performance adjustment layer (requires attorney-drafted compliance structure). Get the operating agreement reviewed by a healthcare transactional attorney, not a general business lawyer.

Distribution frequency

Quarterly distributions are most common, with a year-end true-up based on actual EBITDA. Reserves for equipment, capital improvements, and working capital are held back. Ask to see the historical reserve policy before buying in — a heavily reserved ASC may distribute less than the EBITDA multiple suggests.

Tax treatment of ASC income

This is where ASC ownership gets meaningfully different from W-2 income or even S-Corp income, and where getting the accounting right matters.

It comes through on a K-1

ASC distributions are partnership income (assuming LLC or LP structure — the norm). You receive a Schedule K-1 each year showing your allocable share of ordinary income, plus any guaranteed payments. This income appears on your Schedule E and is taxed as ordinary income at your marginal rate (37% federal for most attending ortho surgeons in 2026).

Self-employment tax vs. NIIT

Whether ASC income is subject to the 15.3%/2.9% SE tax or the 3.8% Net Investment Income Tax (NIIT) depends on your participation level and ownership structure:

• Passive investor: Income is passive; subject to 3.8% NIIT, not SE tax. This is the common structure for surgeon-limited-partners or certain LLC member classifications.
• Active participant / general partner: Subject to SE tax on guaranteed payments; the treatment of distributable share is more complex. IRS rules around passive vs. active ASC participation are not straightforward — a healthcare CPA should classify this correctly each year.

The economic difference is significant: on $300K of ASC income, 3.8% NIIT = $11,400 additional tax; SE tax at 2.9% above the SS wage base = $8,700. The difference is smaller than it looks, but basis tracking and participation classification matter for both audit risk and tax optimization.

The § 199A situation for high-income ortho surgeons

The OBBBA permanently extended the § 199A QBI deduction at 23% for 2026. But the SSTB (specified service trade or business) phaseout eliminates the deduction entirely above $544,600 MFJ taxable income for health-service professionals. Almost all attending orthopedic surgeons are above this threshold.

Whether ASC facility income qualifies as non-SSTB (since it's facility services, not personal physician services) is a debated tax position that requires expert CPA analysis specific to your ownership structure. Don't assume the deduction applies without written guidance from a CPA who works with ASC owners.

Basis tracking

Your tax basis in the ASC partnership interest determines how much of a distribution is non-taxable return of basis vs. taxable gain. Basis starts at your buy-in cost, increases with income allocations, and decreases with distributions and losses. A CPA who doesn't track ASC basis annually creates real risk — distributions in excess of basis are taxable as capital gains.

The regulatory framework: AKS safe harbor

Every orthopedic ASC ownership arrangement operates under the Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), which prohibits any remuneration paid to induce referrals of Medicare/Medicaid patients. The safe harbor at 42 C.F.R. § 1001.952(r) protects surgeon-owned ASC arrangements that meet specific requirements.²

For a surgeon-owned ASC to qualify for the safe harbor, all investors must be:

• Surgeons or surgical group practices who are in a position to refer patients to the facility and perform procedures there
• Not hospital employees, not employed by the ASC, not required to make referrals as a condition of ownership

Additionally, the safe harbor requires:

1. Ownership interests offered on terms not related to past or anticipated referral volume
2. Returns on investment proportional to ownership interest (not case contribution)
3. The ASC is a certified Medicare ASC under 42 C.F.R. Part 416
4. Patients are informed of the referring surgeon's investment interest before referral
5. Investors are not required to use the ASC, and do not receive anything of value in exchange for referrals beyond their pro-rata ownership return

Due diligence before you buy in

The buy-in ROI calculation (which the ASC Investment ROI Calculator handles) is only as good as the inputs. Before committing, review:

Financial documents

• Three years of audited or reviewed financial statements
• Distribution history (what was actually paid vs. what EBITDA suggested should be paid)
• Reserve policy and current reserve balance
• Accounts receivable aging and payer mix breakdown
• Debt schedule (existing equipment loans, real estate mortgage)

Operational metrics

• Case volume trends (total cases, cases per OR day, case mix)
• Payer mix (commercial vs. Medicare vs. Medicaid — relevant given Medicaid ASC reimbursement is often below cost)
• Collections rate and days-in-AR
• OR utilization rate (high utilization limits growth; low utilization limits current income)
• Accreditation status (AAAHC, Joint Commission, or AAAASF) and last survey findings

Legal and structural documents

• Operating agreement (distribution waterfall, capital call rights, drag-along/tag-along, buyout formula on departure or disability, case-volume minimums)
• CMS certification status and any compliance issues
• Real estate situation (owned by partnership vs. leased — lease terms matter for exit valuation)
• Any pending litigation or payer audits

Market position

• Competing ASCs within the service area — how many, what specialties
• Hospital health system expansion plans that could divert commercial volume
• CON (Certificate of Need) requirements in your state that protect the ASC from new competitors

Case study: spine surgeon buying into an existing ASC

The following is a hypothetical model to illustrate the financial mechanics. Your numbers will differ based on your ASC's specifics — use the ASC Investment ROI Calculator for your actual offer.

Scenario: A 5-year-out spine surgeon at a private practice group is offered a 12% stake in the group's 8-OR ambulatory surgery center.

Compare this to the same surgeon who declined the buy-in and invested the $360K in a diversified portfolio instead: at 7% annual return over 10 years, that grows to ~$710K. The ASC ownership advantage — even after accounting for the higher risk — is approximately $4.5M in this scenario.

This math is why failing to buy into a profitable ASC when offered the opportunity is frequently the largest financial mistake orthopedic surgeons make.

Common mistakes

• Declining because $350K feels expensive. The opportunity cost of not buying in at a healthy ASC is typically $3–7M over a career. The buy-in almost always pays back in 2–3 years at an established facility. Refusing because the number looks large is the most expensive mistake in this niche.
• Not modeling case-contribution fit. If you bring 5 cases per month to an ASC that requires 12 to justify your ownership share, you may be a net loser on the deal. Case volume expectations should be explicit in the operating agreement.
• Buying in without reviewing the operating agreement. The buy-in price is not the whole deal. Buyout provisions, right-of-first-refusal terms, capital call rights, and drag-along clauses can significantly alter the investment's real economics. A poor operating agreement can trap you in an ASC or let other partners dilute you before a corporate exit.
• Ignoring the AKS safe harbor structure. An ASC that compensates you based on the volume of cases you personally bring — rather than pro-rata ownership — is operating outside the safe harbor. This exposes all partners to OIG scrutiny, not just the person who structured the deal.
• Skipping CPA coordination on K-1 basis tracking. Distributions in excess of your basis are taxable at capital gains rates, not ordinary income rates. Surgeons who don't track basis correctly either overpay taxes or face audit risk when they eventually exit.
• Over-concentrating without analysis. ASC equity + practice equity + clinical income all correlated to the same local surgical market. One regulatory shift, one hospital system expansion, or one payer contract loss hits all three simultaneously. Understand the concentration risk before treating ASC distributions as the anchor of your retirement plan.
• Waiting too long to buy in. Every year you delay the buy-in is a year of foregone distributions. At many groups, the invitation to join is not open-ended — new slots are offered as existing partners approach retirement. Missing the window often means missing the opportunity entirely.

Equipment and facility tax benefits

If you're involved in a de novo ASC or a facility undergoing major equipment upgrades, the tax treatment of capital investment has improved significantly:

• Section 179 expensing: Up to $2,560,000 of equipment cost can be fully deducted in Year 1 for tax years beginning in 2026 (IRS Rev. Proc. 2025-32), with phase-out beginning at $4,090,000 in total property placed in service.³
• Bonus depreciation: The OBBBA (July 2025) restored 100% bonus depreciation permanently for property placed in service after January 19, 2025. Equipment not covered by Section 179 (e.g., amounts above the phase-out) can still be fully expensed via bonus depreciation.

These deductions flow through your K-1 as allocated losses, which offset your ASC ordinary income. The interaction with passive activity rules and at-risk rules requires a CPA experienced with healthcare partnerships — the deductions are real, but the mechanics are not DIY-friendly.

ASC exit strategies

At some point — retirement, practice sale, or change in local market dynamics — you'll exit your ASC ownership. The three main paths:

Sale to a corporate ASC operator

Major buyers include USPI (Tenet subsidiary), AmSurg, Surgery Partners, SurgCenter Development, and regional platforms. Corporate buyers typically pay 6–10× EBITDA for established orthopedic ASCs with strong volume and good payer mix. For a $5M-EBITDA ASC, that's a $30–50M enterprise value. At 12% ownership, you'd receive $3.6–6M at close.

Corporate acquisitions typically include: 60–75% cash at close, 20–30% rollover equity into the corporate entity (with another exit in 4–7 years), and an ongoing operator agreement. The rollover equity is the "second bite" — see the Private Equity in Orthopedics guide for how these second-bite economics work.

Partner buyout

When you retire or reduce practice, the operating agreement's buyout formula governs what you receive. Most surgeon-owned ASCs use a formula based on a trailing EBITDA multiple, book value of assets, or appraised FMV. Review this formula before you buy in — a formula that prices your interest at book value rather than going-concern value can cost you millions at exit compared to what you'd receive in an arm's-length sale.

Selling your interest to an incoming surgeon

The most common intra-group transition. The incoming surgeon buys your interest at the same formula price used for new buy-ins, or a negotiated FMV. Proceeds are taxed as capital gain to the extent they exceed your adjusted basis.

1. CMS CY 2026 OPPS/ASC Final Rule (CMS-1834-FC) — IPO list removal of 285 musculoskeletal procedures effective Jan 2026.
2. 42 C.F.R. § 1001.952(r) — Anti-Kickback Statute safe harbor for ASC investment interests; Cornell Legal Information Institute, current edition.
3. IRS Rev. Proc. 2025-32 — 2026 inflation adjustments including Section 179 limit ($2,560,000) and phase-out threshold ($4,090,000).
4. HHS OIG Safe Harbor Regulations — overview of AKS safe harbors including ASC arrangement requirements.

Financial values verified against 2026 IRS guidance. ASC economics are illustrative based on ASCA industry data and MGMA 2025 Physician Compensation Report. Individual results vary significantly by facility, market, and ownership terms.